Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2

Descripción del Articulo

A review of renal physiopathology of diabetes mellitus type 2 (DM2) is performed. The paradigmatic focusing of the DM2 treatment by means only on the glycemic control is analyzed. A review of mechanism of action of the so called sodium-dependent glucose cotransporters inhibitors type 2 (SGLT2) is do...

Descripción completa

Detalles Bibliográficos
Autor: Gamarra-González, Dante Américo
Formato: artículo
Fecha de Publicación:2020
Institución:Fundación Instituto Hipólito Unanue
Repositorio:Diagnóstico
Lenguaje:español
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/220
Enlace del recurso:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/220
Nivel de acceso:acceso abierto
Materia:Diabetes Mellitus tipo 2
tratamiento
inhibidores de la SGLT2
Diabetes Mellitus type 2
treatment
SGLT2 inhibitors
id REVFIHU_f2b6989c3efeb94899c8faa4fae1f8f5
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/220
network_acronym_str REVFIHU
network_name_str Diagnóstico
repository_id_str
spelling Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2Papel de la inhibidores de la absorción de la glucosa SGLT2 en el tratamiento de la Diabetes Mellitus tipo 2Gamarra-González, Dante AméricoDiabetes Mellitus tipo 2tratamientoinhibidores de la SGLT2Diabetes Mellitus type 2treatmentSGLT2 inhibitorsA review of renal physiopathology of diabetes mellitus type 2 (DM2) is performed. The paradigmatic focusing of the DM2 treatment by means only on the glycemic control is analyzed. A review of mechanism of action of the so called sodium-dependent glucose cotransporters inhibitors type 2 (SGLT2) is done as well as its indications, cardiovascular safety, pleiotrophic effects, potential side effects and their role in dismissing the severity and mortality due cardiovascular and renal complications. The three main STLT2 inhibitors (dapagliflozin, canagliflozin and empagliflozin) have demonstrated efficacy in the treatment ofDM2 both as mono therapy as well as in combination with insulin and/or oral hypoglycemic agents. They produce a significant weight loss, beneficial effects on blood pressure and changes in lipid profile.Se revisa la fisiopatología renal de la diabetes mellitus tipo 2 (DM2). Se analiza el enfoque que rompe el paradigma de tratar al paciente diabético solo mediante el control de la glicemia. Se revisa el mecanismo de acción de los llamados cotransportadores de sodio-glucosa2 (SGLT2), sus indicaciones, seguridad cardiovascular, efectos pleiotrópicos, los potenciales efectos adversos y su papel en disminuir la severidad y mortalidad por complicaciones cardiovasculares y renales. Los tres principales inhibidores de SGLT2 (dapagliflozina, canagliflozina y empagliflozina) han demostrado eficacia como monoterapia o en combinación con insulina o con otros hipoglicemiantes orales en el tratamiento de la DM2. Provocan pérdida significativa de peso, efecto positivo sobre la presión arterial y producen cambios del perfil lipídico.Fundación Instituto Hipólito Unanue2020-11-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/22010.33734/diagnostico.v59i2.220Diagnóstico; Vol. 59 No. 2 (2020); 69-76Diagnostico; Vol. 59 Núm. 2 (2020); 69-761018-28882709-795110.33734/diagnostico.v59i2reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/220/224Derechos de autor 2020 Dante Américo Gamarra-Gonzálezinfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/2202021-06-04T17:58:46Z
dc.title.none.fl_str_mv Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
Papel de la inhibidores de la absorción de la glucosa SGLT2 en el tratamiento de la Diabetes Mellitus tipo 2
title Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
spellingShingle Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
Gamarra-González, Dante Américo
Diabetes Mellitus tipo 2
tratamiento
inhibidores de la SGLT2
Diabetes Mellitus type 2
treatment
SGLT2 inhibitors
title_short Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
title_full Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
title_fullStr Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
title_full_unstemmed Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
title_sort Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
dc.creator.none.fl_str_mv Gamarra-González, Dante Américo
author Gamarra-González, Dante Américo
author_facet Gamarra-González, Dante Américo
author_role author
dc.subject.none.fl_str_mv Diabetes Mellitus tipo 2
tratamiento
inhibidores de la SGLT2
Diabetes Mellitus type 2
treatment
SGLT2 inhibitors
topic Diabetes Mellitus tipo 2
tratamiento
inhibidores de la SGLT2
Diabetes Mellitus type 2
treatment
SGLT2 inhibitors
description A review of renal physiopathology of diabetes mellitus type 2 (DM2) is performed. The paradigmatic focusing of the DM2 treatment by means only on the glycemic control is analyzed. A review of mechanism of action of the so called sodium-dependent glucose cotransporters inhibitors type 2 (SGLT2) is done as well as its indications, cardiovascular safety, pleiotrophic effects, potential side effects and their role in dismissing the severity and mortality due cardiovascular and renal complications. The three main STLT2 inhibitors (dapagliflozin, canagliflozin and empagliflozin) have demonstrated efficacy in the treatment ofDM2 both as mono therapy as well as in combination with insulin and/or oral hypoglycemic agents. They produce a significant weight loss, beneficial effects on blood pressure and changes in lipid profile.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/220
10.33734/diagnostico.v59i2.220
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/220
identifier_str_mv 10.33734/diagnostico.v59i2.220
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/220/224
dc.rights.none.fl_str_mv Derechos de autor 2020 Dante Américo Gamarra-González
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2020 Dante Américo Gamarra-González
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 59 No. 2 (2020); 69-76
Diagnostico; Vol. 59 Núm. 2 (2020); 69-76
1018-2888
2709-7951
10.33734/diagnostico.v59i2
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1843987758323859456
score 13.062494
Role of the sodium-glucose linked transporte 2 (SGLT2) inhibitor in the treatment of Diabetes Mellitus type 2
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares